Insider Buying: Aileron Therapeutics Inc (NASDAQ:ALRN) SVP Purchases 45,000 Shares of Stock

Aileron Therapeutics Inc (NASDAQ:ALRN) SVP Kathryn Gregory bought 45,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The stock was purchased at an average cost of $0.65 per share, with a total value of $29,250.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Aileron Therapeutics stock traded down $0.01 during midday trading on Thursday, reaching $0.58. The stock had a trading volume of 196,800 shares, compared to its average volume of 260,707. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.04 and a quick ratio of 6.04. The business has a fifty day moving average price of $0.60. Aileron Therapeutics Inc has a 12 month low of $0.44 and a 12 month high of $4.10.

Aileron Therapeutics (NASDAQ:ALRN) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.03). On average, sell-side analysts expect that Aileron Therapeutics Inc will post -1.14 EPS for the current year.



Institutional investors and hedge funds have recently modified their holdings of the business. Deutsche Bank AG grew its position in Aileron Therapeutics by 432.9% in the fourth quarter. Deutsche Bank AG now owns 129,170 shares of the company’s stock valued at $108,000 after acquiring an additional 104,932 shares in the last quarter. Jennison Associates LLC grew its position in Aileron Therapeutics by 649.6% in the first quarter. Jennison Associates LLC now owns 2,040,255 shares of the company’s stock valued at $3,828,000 after acquiring an additional 1,768,073 shares in the last quarter. BlackRock Inc. grew its position in Aileron Therapeutics by 179.6% in the second quarter. BlackRock Inc. now owns 49,485 shares of the company’s stock valued at $36,000 after acquiring an additional 31,787 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in Aileron Therapeutics by 261.6% in the second quarter. Vanguard Group Inc. now owns 333,005 shares of the company’s stock valued at $240,000 after acquiring an additional 240,910 shares in the last quarter. 29.17% of the stock is owned by hedge funds and other institutional investors.

A number of analysts recently commented on the company. ValuEngine raised Aileron Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Zacks Investment Research lowered Aileron Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 9th. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 target price on shares of Aileron Therapeutics in a research report on Wednesday, August 7th. Finally, William Blair reaffirmed an “outperform” rating on shares of Aileron Therapeutics in a research report on Monday, May 6th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Aileron Therapeutics has a consensus rating of “Buy” and a consensus target price of $4.00.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.

Read More: What is a stock split?

Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.